洁瑞品牌怎么样 申请店铺

我要投票 洁瑞在医疗器械行业中的票数:711 更新时间:2026-01-17
洁瑞是哪个国家的品牌?「洁瑞」是 山东威高集团医用高分子制品股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人张华威在2000-12-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力洁瑞品牌出海!将品牌入驻外推网,定制洁瑞品牌推广信息,可以显著提高洁瑞产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

洁瑞怎么样

山东威高集团医用高分子制品股份有限公司(「本公司」)及其附属公司(「本集团」)主要从事研发、生产及销售医用耗材、骨科材料、心脏支架等。本公司为国家高技术研究发展(863)计划成果产业化基地、国家级高新技术企业。本集团主要生产基地位于山东省威海市。

本集团在中国注册,拥有一个由18个销售办事处及21个客户联络中心和107多家城市代表处组成的庞大销售网络,并已建立广泛的客户基础,其产品销售予5,400多家医疗单位和分销商,其中包括医院2800多家、血站400多家、其它医疗单位700多家和逾1,500家贸易公司。

本集团生产的产品种类多达150余种,产品规格超过5000种,产品可分为六大系列,即1)一次性使用医疗耗材及原料,其中包括输液(血)器、注射器、血袋与血液成份分离耗材、采血系列耗材、齿科耗材和麻醉系列耗材等,以及医用PVC粒料和非PVC粒料等;2)骨科材料及工具,主要包括钢板、螺钉等创伤治疗耗材、脊柱系列耗材及正在发展的人工关节系列耗材;3)医用针制品,主要包括静脉针、注射针、留置针、采血针、异形针等系列制品;4)血液净化系列耗材,主要包括穿刺针、血液回路管、透析器等肾科耗材,以及用于红斑狼疮、器官移植排异反应、类风湿关节炎等免疫系统疾病治疗的免疫吸附柱,以及其它正在研发和注册的LDL吸附柱、内毒素吸附柱和乙肝病毒吸附柱等;5)心脏支架产品,主要包括药物涂层心脏支架、球囊等;6)用于药品包装的预充式注射器。

“国家高技术研究发展(863)计划成果产业化基地”、“国家级企业技术中心”,并建有企业博士后工作站。公司积极开展产、学、研合作,与中科院长春应用化学研究所、中科院大连化学物理研究所、中科院沈阳金属研究所、第三军医大学、301医院、哈工大(威海)等科研院所、院校紧密合作,并聘请了10位两院院士做顾问,依托其人才和科研力量,异地建立了九个威高集团研发中心,立足行业制高点,消化吸收国际前沿技术,开发具有自主知识产权的高科技产品。公司有60多个产品达到国内外先进水平,不少产品填补了国内空白,20个产品入选国家863计划、国家重点火炬计划、国家高技术产业示范化工程、国家级重点新产品等国家各类项目,其中药物涂层支架系统、预充式注射器、骨科植入材料等产品打破了国外公司对中国市场的垄断。

集团注重产品品牌的长远发展,强调其产品质量。自2001年11月以来,集团的一次性使用无菌输液器、一次性使用无菌输血器及一次性使用无菌注射器的生产及服务的质量体系获中国医疗器械质量认证中心授予ISO9001:2000认证、中国CMD认证。从1999年12月,集团的输液器、输血器、一次性使用注射器及塑料血袋等产品种类获得由TÜVProductServiceGmbh颁发的CE认证证书以来,本集团已先后获得一次性使用自动取血器、一次性使用CT增强注射器造影剂针筒、一次性使用自毁式安全注射器、自动缩回式安全注射器、骨科器械、金属接骨板,脊柱内固定系统,金属接骨螺钉、带锁髓内钉、一次性使用无菌注射针、一次性使用静脉留置针、无针密闭输液接头等产品及体系的CE认证。于2003年12月5日,集团的产品质量检查中心获中国实验室国家认可委员会评为符合国家测试及定标规定。于2005年6月23日,集团拥有的商标被中国国家工商行政管理总局认定为中国国内医疗器械行业第一个中国驰名商标。

目前,集团的销售主要在中国市场,本集团正积极开拓国际市场,产品已经出口美国、德国、罗马尼亚、澳大利亚和英国等30个国家和地区。

Shandong Weigao group medical polymer products Co., Ltd. (the "company") and its subsidiaries (the "group") are mainly engaged in research and development, production and sales of medical consumables, orthopedic materials, heart stents, etc. The company is the industrialization base of national high-tech research and development (863) plan achievement and national high-tech enterprise. The main production base of the group is located in Weihai City, Shandong Province. Registered in China, the group has a huge sales network consisting of 18 sales offices, 21 customer contact centers and 107 city representative offices, and has established a wide customer base. Its products are sold to more than 5400 medical units and distributors, including more than 2800 hospitals, more than 400 blood stations, more than 700 other medical units and more than 1500 trading companies. The group produces more than 150 kinds of products with more than 5000 specifications, which can be divided into six series, i.e. 1) disposable medical consumables and raw materials, including infusion (blood) devices, syringes, blood bag and blood component separation consumables, blood collection consumables, dental consumables and anesthesia consumables, as well as medical PVC granules and non PVC granules; 2) orthopedic materials And tools, mainly including steel plate, screw and other trauma treatment consumables, spine series consumables and developing artificial joint series consumables; 3) medical needle products, mainly including vein needle, injection needle, retention needle, blood sampling needle, abnormal needle and other series products; 4) blood purification series consumables, mainly including puncture needle, blood circuit tube, dialyzer and other renal consumables, as well as for erythema Immunosorbent columns for the treatment of immune system diseases such as lupus, organ transplantation rejection, rheumatoid arthritis, and other LDL, endotoxin and hepatitis B virus adsorption columns under development and registration; 5) cardiac stent products, mainly including drug coated cardiac stent, balloon, etc.; 6) pre filled syringes for drug packaging. "National High Tech Research and development (863) plan achievement industrialization base", "national enterprise technology center", and built enterprise postdoctoral workstation. The company actively carries out cooperation in production, learning and research, closely cooperates with Changchun Institute of Applied Chemistry of Chinese Academy of Sciences, Dalian Institute of Chemical Physics of Chinese Academy of Sciences, Shenyang Institute of metals of Chinese Academy of Sciences, the Third Military Medical University, 301 Hospital, Harbin University of Technology (Weihai) and other scientific research institutes and colleges, and employs 10 academicians of the two academies as consultants. Relying on their talents and scientific research forces, the company has established nine Weiwei in different places High Tech Group R & D center, based on the industry commanding point, digests and absorbs international cutting-edge technology, and develops high-tech products with independent intellectual property rights. More than 60 products of the company have reached the advanced level at home and abroad, and many products have filled in the gaps at home. 20 products have been selected into various national projects such as the National 863 plan, the national key torch plan, the national high-tech industrial demonstration project, and the national key new products, among which drug coated stent system, pre filled syringe, orthopedic implant materials and other products have broken the foreign companies' commitment to China Market monopoly. The group pays attention to the long-term development of the product brand and emphasizes its product quality. Since November 2001, the group's quality system for the production and service of disposable sterile infusion sets, disposable sterile infusion sets and disposable sterile syringes has been awarded ISO9001:2000 certification and China CMD certification by China Medical Device Quality Certification Center. Since December 1999, the group's infusion sets, blood transfusion sets, disposable syringes and plastic blood bags have obtained CE certification issued by t Ü vproductservicegmbh, the group has successively obtained disposable automatic blood collection sets, disposable CT enhanced syringe contrast agent syringes, disposable self destructed safety syringes and automatic retracted safety syringes CE certification of orthopedic instruments, metal plates, spine internal fixation system, metal screws, interlocking intramedullary nails, disposable sterile injection needles, disposable intravenous indwelling needles, needle free closed infusion joints and other products and systems. On December 5, 2003, the group's product quality inspection center was awarded the National Accreditation Committee of China laboratories as meeting the national testing and calibration regulations. On June 23, 2005, the trademark owned by the group was recognized by the State Administration for Industry and commerce as the first well-known trademark in China's domestic medical device industry. At present, the group's sales are mainly in the Chinese market, and the group is actively exploring the international market. Its products have been exported to 30 countries and regions such as the United States, Germany, Romania, Australia and the United Kingdom.

本文链接: https://brand.waitui.com/b82feb6b3.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

动力电池回收千亿元级市场待启

1月16日,工业和信息化部举行新闻发布会,会上介绍了工业和信息化部等六部门联合印发的《新能源汽车废旧动力电池回收和综合利用管理暂行办法》(简称《管理办法》)。 近年来,我国新能源汽车产业快速发展,产销量持续攀升。同时,随着已经销售使用的新能源汽车动力电池容量衰减步入退役期,废旧动力电池产生量不断增长,我国即将进入动力电池规模化退役阶段。 国家市场监督管理总局此前公布的数据显示,2024年国内动力电池回收量突破30万吨,对应市场规模超480亿元,预计到2030年国内市场规模将突破千亿元。 随着动力电池回收产业的市场规模站上千亿元级,技术成为了这一产业未来竞争的关键之一,其中不仅包括生产工艺技术的持续创新,更涉及数字技术在动力电池回收全生命周期信息溯源管理中的深度应用。(证券时报)

16分钟前

小鹏汽车:小鹏充电今年前两周新增超充站53座

据小鹏汽车消息,小鹏充电2026年第1和2周新增超充站53座,其中S5超快充站5座,S4超快充站37座,超快充站10座,超充站1座。(每经网)

16分钟前

商业航天企业中科宇航完成上市辅导

证监会近日公开发行辅导公示系统显示,中科宇航技术股份有限公司(简称中科宇航)于近日辅导工作完成。(每经网)

16分钟前

现代汽车计划将旗下高端化品牌引入中国市场

据北汽集团消息,2026年1月13日,北汽集团党委书记、董事长张建勇与来访的现代汽车CEO何塞·穆诺兹举行会谈,双方就支持北京现代发展达成多项共识。何塞表示,中国市场始终是其全球战略的核心,将持续加码在中国市场的投入与发展。据介绍,现代汽车将进一步强化技术与人员支持,并将旗下高端化品牌引入中国市场。现代汽车2025年全球销量超727万辆,北京现代全年销量达21万台。根据北京现代此前发布的“智启2030计划”,未来4-5年计划推出20款新车,目标年销50万辆。(界面)

16分钟前

中信证券:看好半导体设备的投资机遇 建议关注高弹性细分龙头

中信证券研报认为,台积电2025年业绩创纪录,2026年资本支出大幅上调,表明了AI算力与先进制程带来的持续红利。面对国内百万片级的先进产能缺口,国内晶圆厂正迎来扩产热潮,为设备市场释放出千亿美元的空间,且国产化率有望实现翻倍增长。基于先进制程与国产替代的双轮驱动,我们看好半导体设备的投资机遇,建议关注具备平台化能力的领军企业及高弹性细分龙头。(财联社)

16分钟前

本页详细列出关于洁瑞的品牌信息,含品牌所属公司介绍,洁瑞所处行业的品牌地位及优势。
咨询